Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients
In older adults, significant weight loss associated with tirzepatide may increase the risk of frailty and mortality, highlighting the need for careful monitoring and clinical decision-making.
Where it sits
this study against the rest of the tirzepatide corpusSummary and findings
This study evaluated the impact of tirzepatide-associated weight loss on incident frailty and mortality risk in adults aged 65 years or older. It measured various frailty-related phenotypes and their association with mortality, ICU admission, and hospitalization. Notably, increased weight loss correlated with higher rates of frailty-related conditions.
Abstract
The U.S. Medicare GLP-1 Bridge program and existing Part D pathways are expanding access to tirzepatide therapy for older adults, including Zepbound through the Bridge for weight management and Mounjaro through Part D coverage for type 2 diabetes. This necessitates identification of clinical vulnerabilities in geriatric patients that may emerge during pharmacologic weight loss. Here we evaluated incident malnutrition, protein-energy malnutrition (PEM), appetite suppression, dehydration, and sarcopenia in the context of tirzepatide-associated weight loss among adults aged 65 years or older, and we quantified associated mortality, intensive care unit (ICU) admission, and hospitalization relative to comparator cohorts of patients who were prescribed other antidiabetic medications (metformin, DPP4 or SGLT2 inhibitors) or underwent bariatric surgery. Incident frailty-related phenotypes rose with larger achieved weight loss. Specifically, anorexia increased from 2.9% (at ≤5% weight loss) to 10.2% (at 30-40%); dehydration from 1.8% to 4.8%; malnutrition from 0.8% to 3.1%; and PEM from 0.5% to 2.9%. Median tirzepatide treatment duration increased from 1.2 months at ≤5% weight loss to 13.2 months at 30-40%, whereas duration was largely invariant by baseline BMI from <30 to >40. The development of frailty phenotypes after tirzepatide initiation was associated with increased rates of mortality (RR 25, 95% CI 18-35), ICU admission (RR 20, 95% CI 16-25), and hospitalization (RR 11, 95% CI 9.8-12) relative to tirzepatide-treated patients who did not develop malnutrition. Baseline features enriched among patients who developed frailty phenotypes after tirzepatide initiation were older age, advanced diabetes, pre-existing MAFLD/MASH, and cardiorenal comorbidities. Physician-reviewed cause-of-death among decedents with incident frailty phenotypes after tirzepatide initiation showed respiratory failure, septic shock, advanced malignancy, and multiorgan failure as leading causes of death. Overall, in this observational study of Medicare-age-eligible adults, incident frailty phenotyping during tirzepatide-associated weight loss identified vulnerable subgroups with baseline cardiometabolic burden, highlighting the need for comprehensive clinical decision support and multimodal patient monitoring with increasing weight-loss.
Background
The paper addresses the clinical question of how significant weight loss from tirzepatide affects frailty and mortality risk in older adults, a demographic often at higher risk for these outcomes. Previous studies have indicated that weight loss can influence health outcomes, but the specific effects of tirzepatide in this age group had not been thoroughly evaluated. Understanding this relationship is crucial for assessing the broader implications of tirzepatide use in older populations.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.